Innovation is undoubtedly the key element in China’s healthcare investment scenario and early-stage venture capital funds continue to back home-grown new drug development with a total of 15 deals in the third quarter. The biggest deal was valued at up to $66m.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?